In silico identification of potential inhibitors with higher potency than bumetanide targeting NKCC1: An important ion co-transporter to treat neurological disorders
Na + -K + -2Cl-cotransporter 1 (NKCC1) plays an important role in intracellular ionic homeostasis and cell volume regulation in the brain. Pathological activation of brain NKCC1 is associated with many brain disorders, including ischemic stroke, traumatic brain injury, epilepsy, neonatal seizure and...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6dbfcef71e5f44a6a6a914e6b7603b54 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:6dbfcef71e5f44a6a6a914e6b7603b54 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:6dbfcef71e5f44a6a6a914e6b7603b542021-11-12T04:42:13ZIn silico identification of potential inhibitors with higher potency than bumetanide targeting NKCC1: An important ion co-transporter to treat neurological disorders2352-914810.1016/j.imu.2021.100777https://doaj.org/article/6dbfcef71e5f44a6a6a914e6b7603b542021-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2352914821002495https://doaj.org/toc/2352-9148Na + -K + -2Cl-cotransporter 1 (NKCC1) plays an important role in intracellular ionic homeostasis and cell volume regulation in the brain. Pathological activation of brain NKCC1 is associated with many brain disorders, including ischemic stroke, traumatic brain injury, epilepsy, neonatal seizure and autism, suggesting NKCC1 as a potential drug target. Several preclinical and clinical studies used Bumetanide, one of the “loop” diuretic drugs, to inhibit brain NKCC1 activity in neurodevelopmental and neurological disorders. However, poor brain penetration and potent diuretic effect limit its use. Thereby, we selected 1930 compounds, each having the capacity to penetrate into the brain to unmask the best candidates that can act as potent inhibitors for NKCC1 to curb this problem. Molecular docking was performed using PyRx to determine the maximum binding affinities (ranging from −9.3 to 9.0 kcal/mol)among the compounds and the NKCC1 to finally lay out the four top ranked compounds. ADMET analysis revealed that all the four compounds are safer drug candidates and that none of them posed either AMES toxicity or carcinogenicity when filtered on toxicological properties. Selected top-ranked each four compounds along with control (Bumetanide) underwent molecular dynamics (MD) simulations for 100ns each to validate the docking interactions where all four compounds with pubchem CID: (71753382), Pubchem CID:(5740383), Pubchem CID: (71692222) and Pubchem CID: (3442850) are highly supported by root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), radius of gyration (Rg), SASA (Solvent accessible Surface Area) value and Hydrogen bond analysis. Thus, our in silico investigation exhibits all four compounds as potent inhibitors for NKCC1.Arpita Singha RoyMd Sad Salabi SawravMd Shahadat HossainFatema Tuz JohuraSk. Faisal AhmedIthmam HamiMd Kobirul IslamHasan Al RezaMohammad Iqbal H. BhuiyanNewaz Mohammed BahadurMd Mizanur RahamanElsevierarticleNKCC1CNS Compound libraryIn silico ScreeningADMETMD simulationLoop diureticsComputer applications to medicine. Medical informaticsR858-859.7ENInformatics in Medicine Unlocked, Vol 27, Iss , Pp 100777- (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
NKCC1 CNS Compound library In silico Screening ADMET MD simulation Loop diuretics Computer applications to medicine. Medical informatics R858-859.7 |
| spellingShingle |
NKCC1 CNS Compound library In silico Screening ADMET MD simulation Loop diuretics Computer applications to medicine. Medical informatics R858-859.7 Arpita Singha Roy Md Sad Salabi Sawrav Md Shahadat Hossain Fatema Tuz Johura Sk. Faisal Ahmed Ithmam Hami Md Kobirul Islam Hasan Al Reza Mohammad Iqbal H. Bhuiyan Newaz Mohammed Bahadur Md Mizanur Rahaman In silico identification of potential inhibitors with higher potency than bumetanide targeting NKCC1: An important ion co-transporter to treat neurological disorders |
| description |
Na + -K + -2Cl-cotransporter 1 (NKCC1) plays an important role in intracellular ionic homeostasis and cell volume regulation in the brain. Pathological activation of brain NKCC1 is associated with many brain disorders, including ischemic stroke, traumatic brain injury, epilepsy, neonatal seizure and autism, suggesting NKCC1 as a potential drug target. Several preclinical and clinical studies used Bumetanide, one of the “loop” diuretic drugs, to inhibit brain NKCC1 activity in neurodevelopmental and neurological disorders. However, poor brain penetration and potent diuretic effect limit its use. Thereby, we selected 1930 compounds, each having the capacity to penetrate into the brain to unmask the best candidates that can act as potent inhibitors for NKCC1 to curb this problem. Molecular docking was performed using PyRx to determine the maximum binding affinities (ranging from −9.3 to 9.0 kcal/mol)among the compounds and the NKCC1 to finally lay out the four top ranked compounds. ADMET analysis revealed that all the four compounds are safer drug candidates and that none of them posed either AMES toxicity or carcinogenicity when filtered on toxicological properties. Selected top-ranked each four compounds along with control (Bumetanide) underwent molecular dynamics (MD) simulations for 100ns each to validate the docking interactions where all four compounds with pubchem CID: (71753382), Pubchem CID:(5740383), Pubchem CID: (71692222) and Pubchem CID: (3442850) are highly supported by root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), radius of gyration (Rg), SASA (Solvent accessible Surface Area) value and Hydrogen bond analysis. Thus, our in silico investigation exhibits all four compounds as potent inhibitors for NKCC1. |
| format |
article |
| author |
Arpita Singha Roy Md Sad Salabi Sawrav Md Shahadat Hossain Fatema Tuz Johura Sk. Faisal Ahmed Ithmam Hami Md Kobirul Islam Hasan Al Reza Mohammad Iqbal H. Bhuiyan Newaz Mohammed Bahadur Md Mizanur Rahaman |
| author_facet |
Arpita Singha Roy Md Sad Salabi Sawrav Md Shahadat Hossain Fatema Tuz Johura Sk. Faisal Ahmed Ithmam Hami Md Kobirul Islam Hasan Al Reza Mohammad Iqbal H. Bhuiyan Newaz Mohammed Bahadur Md Mizanur Rahaman |
| author_sort |
Arpita Singha Roy |
| title |
In silico identification of potential inhibitors with higher potency than bumetanide targeting NKCC1: An important ion co-transporter to treat neurological disorders |
| title_short |
In silico identification of potential inhibitors with higher potency than bumetanide targeting NKCC1: An important ion co-transporter to treat neurological disorders |
| title_full |
In silico identification of potential inhibitors with higher potency than bumetanide targeting NKCC1: An important ion co-transporter to treat neurological disorders |
| title_fullStr |
In silico identification of potential inhibitors with higher potency than bumetanide targeting NKCC1: An important ion co-transporter to treat neurological disorders |
| title_full_unstemmed |
In silico identification of potential inhibitors with higher potency than bumetanide targeting NKCC1: An important ion co-transporter to treat neurological disorders |
| title_sort |
in silico identification of potential inhibitors with higher potency than bumetanide targeting nkcc1: an important ion co-transporter to treat neurological disorders |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/6dbfcef71e5f44a6a6a914e6b7603b54 |
| work_keys_str_mv |
AT arpitasingharoy insilicoidentificationofpotentialinhibitorswithhigherpotencythanbumetanidetargetingnkcc1animportantioncotransportertotreatneurologicaldisorders AT mdsadsalabisawrav insilicoidentificationofpotentialinhibitorswithhigherpotencythanbumetanidetargetingnkcc1animportantioncotransportertotreatneurologicaldisorders AT mdshahadathossain insilicoidentificationofpotentialinhibitorswithhigherpotencythanbumetanidetargetingnkcc1animportantioncotransportertotreatneurologicaldisorders AT fatematuzjohura insilicoidentificationofpotentialinhibitorswithhigherpotencythanbumetanidetargetingnkcc1animportantioncotransportertotreatneurologicaldisorders AT skfaisalahmed insilicoidentificationofpotentialinhibitorswithhigherpotencythanbumetanidetargetingnkcc1animportantioncotransportertotreatneurologicaldisorders AT ithmamhami insilicoidentificationofpotentialinhibitorswithhigherpotencythanbumetanidetargetingnkcc1animportantioncotransportertotreatneurologicaldisorders AT mdkobirulislam insilicoidentificationofpotentialinhibitorswithhigherpotencythanbumetanidetargetingnkcc1animportantioncotransportertotreatneurologicaldisorders AT hasanalreza insilicoidentificationofpotentialinhibitorswithhigherpotencythanbumetanidetargetingnkcc1animportantioncotransportertotreatneurologicaldisorders AT mohammadiqbalhbhuiyan insilicoidentificationofpotentialinhibitorswithhigherpotencythanbumetanidetargetingnkcc1animportantioncotransportertotreatneurologicaldisorders AT newazmohammedbahadur insilicoidentificationofpotentialinhibitorswithhigherpotencythanbumetanidetargetingnkcc1animportantioncotransportertotreatneurologicaldisorders AT mdmizanurrahaman insilicoidentificationofpotentialinhibitorswithhigherpotencythanbumetanidetargetingnkcc1animportantioncotransportertotreatneurologicaldisorders |
| _version_ |
1718431236271112192 |